keyword
MENU ▼
Read by QxMD icon Read
search

Keratoacanthoma

keyword
https://www.readbyqxmd.com/read/28628690/case-report-of-multiple-keratoacanthomas-and-squamous-cell-carcinomas-in-a-patient-receiving-pembrolizumab
#1
Soham Chaudhari, Argentina Leon, Ethan Levin, Isaac Neuhaus, Wilson Liao
<p>PD-1 is expressed on antigen-stimulated T cells and induces a downstream signaling pathway that works by negative feedback to inhibit T cell proliferation, cytokine release, and cytotoxicity. PD-1 antibodies increase tumor cell killing peripherally and have a role in advanced melanoma treatment. We describe a case of an 84 year old female with stage 4 metastatic melanoma in a trial of the PD-1 inhibitor pembrolizumab who developed multiple keratoacanthomas after several months of treatment. While keratoacanthomas have been reported in patients taking BRAF inhibitors, no such reports exist for those on pembrolizumab, making this the first case report to point out this association for further investigative studies...
May 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28611627/panniculitis-associated-with-mek-inhibitor-therapy-an-uncommon-adverse-effect
#2
Miruna Negulescu, Florian Deilhes, Vincent Sibaud, Emilie Tournier, Laurence Lamant, Serge Boulinguez, Nicolas Meyer
The combination of MEK inhibitor (cobimetinib, trametinib) and BRAF inhibitor (vemurafenib, dabrafenib) is now the first-line treatment in patients with BRAF V600-mutated metastatic melanoma. This association reduces cutaneous adverse events induced by BRAF inhibitors alone, including photosensitivity, hand-foot syndrome, hyperkeratosis, alopecia, skin papillomas, keratoacanthomas, and squamous-cell carcinomas. While panniculitis has exceptionally been reported with BRAF inhibitors, this rare side effect has never been described with the use of MEK inhibitors...
January 2017: Case Reports in Dermatology
https://www.readbyqxmd.com/read/28584672/keratoacanthoma-of-the-nasal-septum-secondary-to-ranibizumab-use
#3
Jason E Cohn, Hilary M Caruso Sales, Giang Huong Nguyen, Harvey Spector, Kenneth Briskin
Keratoacanthoma (KA) is a benign epithelial tumor that typically presents as a firm, cone-shaped, flesh-colored nodule with a central horn-filled crater. KA is considered to be a low-grade variant of squamous cell carcinoma (SCC). We report a rare case of a 72-year-old male who presented with a KA involving the nasal septum, possibly related to ranibizumab use. A flesh-colored lesion on the right anterior nasal septum lesion was visualized on examination. Histologic examination revealed a well-circumscribed, dome-shaped central crater filled with keratin, well-differentiated squamous epithelium with ground-glass cytoplasm with pushing margins, and intraepithelial microabscesses establishing the diagnosis of KA...
2017: Case Reports in Pathology
https://www.readbyqxmd.com/read/28543888/multiple-keratoacanthoma-centrifugum-marginatum-in-a-young-boy-and-review-of-the-literature
#4
S Dogra, K Vinay, U N Saikia, D De, S Handa
No abstract text is available yet for this article.
May 24, 2017: Clinical and Experimental Dermatology
https://www.readbyqxmd.com/read/28501937/expression-of-pd-l1-in-keratoacanthoma-and-different-stages-of-progression-in-cutaneous-squamous-cell-carcinoma
#5
Thilo Gambichler, Martha Gnielka, Ines Rüddel, Eggert Stockfleth, Markus Stücker, Lutz Schmitz
BACKGROUND: Programmed cell death 1 (PD-1) and its ligands (PD-L1) play a major role in the immune responses of a variety of cancers. OBJECTIVES: To investigate the expression of PD-L1 in different progression forms of cutaneous squamous cell carcinoma (cSCC) and keratoacanthoma (KA). METHODS: We performed immunohistochemical staining of 21 KA, 26 actinic keratoses (AK), 20 Bowen´s diseases (BD), and 26 high-risk cSCC. The staining patterns were assessed using the tumour proportion score and staining intensity evaluation...
May 13, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/28501764/open-label-multicentre-safety-study-of-vemurafenib-in%C3%A2-3219-patients-with-braf-v600-mutation-positive-metastatic-melanoma-2-year-follow-up-data-and-long-term-responders-analysis
#6
Christian U Blank, James Larkin, Ana M Arance, Axel Hauschild, Paola Queirolo, Michele Del Vecchio, Paolo A Ascierto, Ivana Krajsova, Jacob Schachter, Bart Neyns, Claus Garbe, Vanna Chiarion Sileni, Mario Mandalà, Helen Gogas, Enrique Espinosa, Geke A P Hospers, Wilson H Miller, Susan Robson, Martina Makrutzki, Vladan Antic, Michael P Brown
BACKGROUND: The orally available BRAF kinase inhibitor vemurafenib is an effective and tolerable treatment option for patients with metastatic melanoma harbouring BRAF(V600) mutations. We assessed the safety of vemurafenib in a large population of patients with few alternative treatment options; we report updated 2-year safety. METHODS: This was an open-label, multicentre study of vemurafenib (960 mg bid) in patients with previously treated or untreated BRAF mutation-positive metastatic melanoma (cobas(®) 4800 BRAF V600 Mutation Test)...
May 11, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28479697/keratoacanthoma-of-the-lip-a-case-report-with-emphasis-on-histogenesis
#7
Pooja Kamath, Treville Pereira, Mayura Chande, Subraj Shetty
Keratoacanthoma (KA) is a benign epithelial tumor which presents clinically as a proliferating dome-shaped keratin-filled crater. The lesion occurs predominantly upon sun-exposed areas of the body and is known to arise from hair follicle. Actinic rays are a major contributing factor in the etiology. It simulates grossly as well as microscopically a low-grade squamous cell carcinoma. KAs occur habitually on the mucous membrane as well, but their origin in these cases is debatable, owing to the lack of hair follicles in these sites...
January 2017: Journal of Oral and Maxillofacial Pathology: JOMFP
https://www.readbyqxmd.com/read/28467522/eruptive-keratoacanthomas-associated-with-pembrolizumab-therapy
#8
Azael Freites-Martinez, Bernice Y Kwong, Kerri E Rieger, Daniel G Coit, A Dimitrios Colevas, Mario E Lacouture
Importance: To our knowledge, there have been no previous reports of eruptive keratoacanthomas (KAs) in patients receiving pembrolizumab. Objective: To report the cases of 3 consecutive patients with pembrolizumab-induced eruptive KAs and their management. Design, Setting, and Participants: Case report study of 3 patients from 2 centers with pembrolizumab-treated cancer who all developed eruptive KAs. Interventions: All 3 patients had AK treatment with clobetasol ointment and intralesional triamcinolone; 2 patients also underwent open superficial cryosurgery...
May 3, 2017: JAMA Dermatology
https://www.readbyqxmd.com/read/28454431/cytokeratin-17-and-ki-67-immunohistochemical-markers-for-the-differential-diagnosis-of-keratoacanthoma-and-squamous-cell-carcinoma
#9
Cem Leblebici, Esra Pasaoglu, Canan Kelten, Seher Darakci, Nevra Dursun
The clinical and histopathological distinction between keratoacanthoma (KA) and squamous cell carcinoma (SCC) is essential, but frequently difficult to make. The utility of CK17 and Ki-67 expression in distinguishing between KA and SCC was investigated. Immunohistochemical staining patterns for CK17 and Ki-67 were evaluated in 24 KA and 27 SCC cases. The pattern of staining was evaluated as central, peripheral or diffuse, according to the basal/peripheral and suprabasal/central cell staining of tumor lobules...
April 2017: Oncology Letters
https://www.readbyqxmd.com/read/28414858/keratoacanthoma-like-growths-of-incontinentia-pigmenti-successfully-treated-with-intralesional-methotrexate
#10
Brittany Barros, Klaus Helm, Andrea Zaenglein, Elizabeth Seiverling
We report the case of a 17-year-old girl with incontinentia pigmenti who developed multiple large hyperkeratotic tumors within Blaschkoid hyperpigmented patches on her left leg. Biopsy demonstrated an endoexophytic nodule with irregular invaginations of keratinizing squamous epithelium and a central keratin-filled crater, consistent with keratoacanthoma-like lesions of incontinentia pigmenti. The tumors were successfully treated with intralesional methotrexate.
April 17, 2017: Pediatric Dermatology
https://www.readbyqxmd.com/read/28392667/a-case-of-exophytic-pilomatricoma-clinically-resembling-keratoacanthoma
#11
Seung Hyun Chun, Chang Min Kim, Ji Min Lee, Il-Hwan Kim
No abstract text is available yet for this article.
April 2017: Annals of Dermatology
https://www.readbyqxmd.com/read/28345450/erratum
#12
(no author information available yet)
Weber, K. (2017). Differences in Types and Incidence of Neoplasms in Wistar Han and Sprague-Dawley Rats. J Toxicol Pathol45, 64-75. (Original DOI: 10.1177/0192623316672075) In the January 2017 issue of Toxicologic Pathology, a number of in text Table citations were incorrectly labeled. The following are the sentences with corrected Table number (this has also been corrected in the online version): Many fewer neoplasms are recorded for the endocrine pancreas compared with islet cell tumor incidences (Table 3)...
January 1, 2017: Toxicologic Pathology
https://www.readbyqxmd.com/read/28332728/keratoacanthoma-en-plaque-nodule-a-brief-report-of-the-clinicopathological-features-of-five-cases
#13
Noriyuki Misago, Shin-Ichi Ansai, Takaya Fukumoto, Takashi Anan, Tomokazu Nakao
Keratoacanthoma (KA) is characterized by exoendophytic growth with a central keratin-filled crater, representing the crateriform architecture. We herein report five rare cases of KA without a central keratin-filled crater. These KA cases histopathologically showed that one or a few infundibular structures/isthmic lobules had their own open keratotic pores on the surface without a common merged keratotic plug/horn, clinically representing verrucous (keratotic) plaque/nodule, namely, "KA en plaque/nodule". KA rarely but on occasion does show verrucous plaque (or nodular) lesions without a central keratin-filled crater, as the notion that KA invariably shows crateriform architecture is nonsensical...
March 23, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28323777/msh6-past-and-present-and-muir-torre-syndrome-connecting-the-dots
#14
REVIEW
Meera Mahalingam
Sebaceous neoplasms such as adenoma, sebaceoma, and carcinoma, although sporadic in their occurrence, are clinically significant because of their association with Muir-Torre syndrome (MTS). MTS is a rare autosomal dominant genodermatosis characterized by the occurrence of sebaceous neoplasms and/or keratoacanthomas and visceral malignancies. MTS is usually the result of germline mutations in the DNA mismatch repair genes MSH2 and, albeit less commonly, MLH1. Although less know, MSH6 is yet another key player...
April 2017: American Journal of Dermatopathology
https://www.readbyqxmd.com/read/28296794/solitary-large-keratoacanthomas-of-the-head-and-neck-an-observational-study
#15
Anthony M Rossi, Brian Park, Bernice Qi, Erica H Lee, Klaus J Busam, Kishwer S Nehal
BACKGROUND: Solitary large keratoacanthomas (KAs) of the head and neck present a management dilemma, as no reliable means to predict the clinical course is available. Although typically considered a low-grade tumor, KAs are reported to invade/metastasize, prompting more aggressive treatment. There is little published regarding factors that predict when a KA behaves more like an aggressive squamous cell carcinoma (SCC). OBJECTIVE: To study the clinical and pathologic features of large solitary head and neck KAs and assess response to intralesional methotrexate (IL-MTX) as well as predictors of clinical course...
June 2017: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
https://www.readbyqxmd.com/read/28288451/how-to-diagnose-and-classify-tattoo-complications-in-the-clinic-a-system-of-distinctive-patterns
#16
Jørgen Serup
Tattoo complications represent a broad spectrum of clinical entities and disease mechanisms. Infections are known, but chronic inflammatory reactions have hitherto been inconsistently reported and given many interpretations and terms. A clinical classification system of distinct patterns with emphasis on inflammatory tattoo reactions is introduced. Allergic reactions prevalent in red tattoos and often associated with azo pigments are manifested as the 'plaque elevation', 'excessive hyperkeratosis', and 'ulceronecrotic' patterns...
2017: Current Problems in Dermatology
https://www.readbyqxmd.com/read/28270315/keratoacanthoma-centrifugum-marginatum-response-to-acitretin
#17
Abdulmohti Hawilo, Ines Zaraa, Dalenda El Euch, Mourad Mokni, Samir Boubaker, Amel Ben Osman
A previously healthy 70-year-old woman presented with a 5-month history of an asymptomatic keratotic, papulonodular plaque on her right forearm. The lesion started as a follicular papule followed by progressive peripheral proliferation. No record of trauma, contact with any chemicals, use of immunosuppressive drugs, or history of neoplasm was noted. Clinical examination showed an arciform plaque of 10×5 cm, with infiltrated raised borders and central atrophy (Figure 1). Drops of yellowish material exuded from the coalescent nodules constituting an elevated and indurate border...
2017: Skinmed
https://www.readbyqxmd.com/read/28256761/advances-in-histopathological-diagnosis-of-keratoacanthoma
#18
REVIEW
Toshihiro Takai
Keratoacanthoma is a common epithelial lesion, but its nature is controversial. Although a distinct crateriform appearance is a hallmark of keratoacanthoma, other benign or malignant skin lesions may show a similar architecture. Moreover, as lesions diagnosed as conventional keratoacanthoma may show malignant behavior, some authors consider keratoacanthoma to be a variant of squamous cell carcinoma, whereas others consider it as a distinct self-resolving squamous proliferative lesion. The controversy seems to originate from the diverse behavior of keratoacanthoma-like epithelial lesions...
March 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28247230/update-from-the-4th-edition-of-the-world-health-organization-of-head-and-neck-tumours-tumours-of-the-oral-cavity-and-mobile-tongue
#19
Susan Müller
There have been several additions and deletions in Chapter 4 on Tumours of the oral cavity and mobile tongue in the 2017 fourth edition of the World Health Organization Classification of Tumours of the Head and Neck. This chapter excludes the oropharynx, which now is a stand-alone chapter acknowledging the uniqueness of the oropharynx from the oral cavity. New entries in Chapter 4 include rhabdomyoma, haemangioma, schwannoma, neurofibroma and myofibroblastic sarcoma in the section titled Soft tissue and neural tumours...
March 2017: Head and Neck Pathology
https://www.readbyqxmd.com/read/28222231/two-cases-of-anti-programmed-cell-death-1-associated-bullous-pemphigoid-like-disease-and-eruptive-keratoacanthomas-featuring-combined-histopathology
#20
Justin P Bandino, David M Perry, Christina E Clarke, Richard M Marchell, Dirk M Elston
Programmed cell death protein 1 (PD-1) inhibitors (pembrolizumab, nivolumab) are novel immunotherapies revolutionizing the management of advanced malignancy with an improved adverse effect profile, yet the immune-related side effects are still being characterized.(1,2) We report the unique concurrence of bullous pemphigoid-like disease (BP) with keratoacanthomas and squamous cell carcinomas in two patients receiving anti-PD-1 immunotherapy for metastatic melanoma. This article is protected by copyright. All rights reserved...
February 21, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
keyword
keyword
50881
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"